<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03037944</url>
  </required_header>
  <id_info>
    <org_study_id>ASAD0316</org_study_id>
    <nct_id>NCT03037944</nct_id>
  </id_info>
  <brief_title>Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri</brief_title>
  <acronym>LNG-IUDvsCOCs</acronym>
  <official_title>Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams Maternity Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the efficacy of LNG - IUD (Levonorgestrel releasing intrauterine&#xD;
      device) Versus Low dose COCs (combined oral contraceptive pills) on management of heavy&#xD;
      menstrual bleeding and Dysmenorrhea caused by Adenomyosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Levonorgestrel releasing intrauterine device will be MetraPlant-E, which is used in this&#xD;
      study in group A, is a modified Levonorgestrel -releasing intrauterine system from the old&#xD;
      IUD - Intrauterine Device &quot;Metraplant&quot;, MetraPlant-E design has a T-shaped frame containing&#xD;
      Levonorgestrel and Ethylene Vinyl Acetate as well as Barium Sulphate to make it radio-opaque,&#xD;
      All the &quot;T&quot; frame, the bulb of 20 mm length and sleeves contain: Ethylene Vinyl Acetate,&#xD;
      Levonorgestrel and Barium Sulphate, which ensures more exposure of the endometrial surface to&#xD;
      the system and hence expected more endometrial suppression.&#xD;
&#xD;
      It consists of Levonorgestrel Hormone (60 mg), Ethylene Vinyl Acetate (120 mg) &amp; Barium&#xD;
      Sulphate (20 mg) Metraplant-E is designed without any coat membrane, which will help in more&#xD;
      rise in Levonorgestrel level (higher initial release). The high initial release of&#xD;
      Levonorgestrel (reached more than 28Âµg/24hrs in Metraplant-E in this study of in-vitro&#xD;
      release) may help in early stoppage of bleeding in patients who suffer from irregular&#xD;
      bleeding.&#xD;
&#xD;
      Women in group A will receive IUD - Intrauterine Device- during menstruation .It will be&#xD;
      inserted into uterus in similar procedure to non-hormonal IUD .Pelvic exam will be done, the&#xD;
      vagina will hold open with speculum, grasping the cervix, measuring uterine length and proper&#xD;
      insertion of IUD - Intrauterine Device by non-touch technic. Women will receive proper&#xD;
      antibiotics after insertion.&#xD;
&#xD;
      Group B will receive combined oral contraceptive pills (Yasmin) which will be Monophasic&#xD;
      pills have a constant dose of both estrogen and progestin in each of the hormonal active&#xD;
      pills throughout the entire cycle . Yasmin (ethinyl estradiol 0.03 mg/ drospirenone 3 mg)&#xD;
      tablets, it provides an oral contraceptive regimen, it will be used continuously for 6 months&#xD;
      with stoppage after 3 months for withdrawal bleeding.&#xD;
&#xD;
      Both treatment arms (Metraplant E and Yasmin) will be followed up after 3 months and 6 month&#xD;
      of patients' recruitment. Assessment of pain related symptoms will be done using visual&#xD;
      analogue scale pain score, while assessment of menstrual improvement will be done using&#xD;
      menstrual diary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of pain by pain measurement score</measure>
    <time_frame>6 Months</time_frame>
    <description>measurement of the pain score by questionnaire form filled by patients. this questionnaire is evaluated by numbers corresponding to each answer chosen by patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of bleeding days</measure>
    <time_frame>6 Months</time_frame>
    <description>number of bleeding days is reported by patients and compared to pre- treatment conditions to evaluate the bleeding painful process duration and whether the intervention treatment had any relieving effect</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Adenomyosis</condition>
  <arm_group>
    <arm_group_label>Group A-LNG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Levonorgestrel releasing intrauterine device - IUD- will be Metraplant-E, which is used in this study for group A, is a modified Levonorgestrel-releasing intrauterine system from the old IUD &quot;Metraplant&quot;, Metraplant-E design has a T-shaped frame containing Levonorgestrel and Ethylene Vinyl Acetate as well as Barium Sulphate to make it radio-opaque, All the &quot;T&quot; frame, the bulb of 20 mm length and sleeves contain: Ethylene Vinyl Acetate, Levonorgestrel and Barium Sulphate, ensure more exposure of the endometrial surface to the system and hence expect more endometrial suppression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B-COCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B will receive combined oral contraceptive pills (Yasmin) COCs which will be Monophasic pills that have a constant dose of both estrogen and progestins in each of the hormonal active pills throughout the entire cycle . Yasmin (ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets, provides an oral contraceptive regimen, it will be used continuously for 6 months with stoppage after 3 months for withdrawal bleeding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yasmin</intervention_name>
    <description>(ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets</description>
    <arm_group_label>Group B-COCs</arm_group_label>
    <other_name>drospirenone and ethinyl estradiol tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Metraplant-E</intervention_name>
    <description>Levonorgestrel-releasing Intrauterine System modified levonorgestrel-releasing intrauterine system from the old IUD &quot;Metraplant&quot;, modified by Azzam 2013</description>
    <arm_group_label>Group A-LNG</arm_group_label>
    <other_name>Metraplant-E- Levonorgestrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women patient aged 30-45 years&#xD;
&#xD;
          -  Diagnosed adenomyosis by transvaginal ultrasound or MRI or 3D ultrasound&#xD;
&#xD;
          -  Patient complains of heavy menstrual bleeding or dysmenorrhea or both&#xD;
&#xD;
          -  Living in a nearby area to make follow-up reasonably possible&#xD;
&#xD;
          -  Planning for birth spacing for at least 2 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or seeking fertility&#xD;
&#xD;
          -  Severe underlying comorbidities (hepatic, oncological)&#xD;
&#xD;
          -  Pelvic inflammatory disease&#xD;
&#xD;
          -  Other cervical or uterine pathologies&#xD;
&#xD;
          -  Deep venous thromboembolism&#xD;
&#xD;
          -  Hormonal therapy contraindications&#xD;
&#xD;
          -  Endometriosis or fibroid&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Es Abbas, Lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University - Maternity Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karim Mo Labib, Lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University - Maternity Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karim AH Labib, Assistant</last_name>
    <role>Study Chair</role>
    <affiliation>Ain Shams University - Maternity Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asmaa Ma Mohamdy, Bachelor</last_name>
    <phone>+201008340829</phone>
    <email>dr.asmaamamdoh@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Es Abbas, Lecturer</last_name>
    <phone>+201007644642</phone>
    <email>moh_3smat@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ain Shams University - Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asmaa MA Mohamdy, Bachelors</last_name>
      <phone>+201008340829</phone>
      <email>dr.asmaamamdoh@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Karim Ah Wahba, Asst.Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karim Mo Labib, Lecturer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Es Abbass, Lecturer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Benagiano G, Brosens I, Habiba M. Structural and molecular features of the endomyometrium in endometriosis and adenomyosis. Hum Reprod Update. 2014 May-Jun;20(3):386-402. doi: 10.1093/humupd/dmt052. Epub 2013 Oct 18. Review.</citation>
    <PMID>24140719</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>July 10, 2016</study_first_submitted>
  <study_first_submitted_qc>January 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <last_update_submitted>January 28, 2017</last_update_submitted>
  <last_update_submitted_qc>January 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams Maternity Hospital</investigator_affiliation>
    <investigator_full_name>Asmaa Mamdoh Mohamdy</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Adenomyosis</keyword>
  <keyword>Contraceptive pills</keyword>
  <keyword>Levonorgestrel-releasing Intrauterine System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomyosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

